7595717

Source:http://linkedlifedata.com/resource/pubmed/id/7595717

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0030705, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0205488, umls-concept:C0218640, umls-concept:C0338361, umls-concept:C0599991, umls-concept:C0686907, umls-concept:C1261473, umls-concept:C1704410
pubmed:issue	10
pubmed:dateCreated	1995-12-4
pubmed:abstractText	This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobins, http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide, http://linkedlifedata.com/resource/pubmed/chemical/Mesna, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/lenograstim
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0732-183X
pubmed:author	pubmed-author:BonichonFF, pubmed-author:BuiB NBN, pubmed-author:ChevallierBB, pubmed-author:ChevreauCC, pubmed-author:CupissolDD, pubmed-author:FargeotPP, pubmed-author:KrakowskiII, pubmed-author:LoweM RMR, pubmed-author:Maugard-LouboutinCC, pubmed-author:ThyssAA
pubmed:issnType	Print
pubmed:volume	13
pubmed:owner	NLM
pubmed:authorsComplete	N
pubmed:pagination	2629-36
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:7595717-Adult, pubmed-meshheading:7595717-Aged, pubmed-meshheading:7595717-Alopecia, pubmed-meshheading:7595717-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7595717-Dacarbazine, pubmed-meshheading:7595717-Double-Blind Method, pubmed-meshheading:7595717-Doxorubicin, pubmed-meshheading:7595717-Female, pubmed-meshheading:7595717-Follow-Up Studies, pubmed-meshheading:7595717-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:7595717-Hematuria, pubmed-meshheading:7595717-Hemoglobins, pubmed-meshheading:7595717-Humans, pubmed-meshheading:7595717-Ifosfamide, pubmed-meshheading:7595717-Injections, Subcutaneous, pubmed-meshheading:7595717-Length of Stay, pubmed-meshheading:7595717-Leukocyte Count, pubmed-meshheading:7595717-Male, pubmed-meshheading:7595717-Mesna, pubmed-meshheading:7595717-Middle Aged, pubmed-meshheading:7595717-Nausea, pubmed-meshheading:7595717-Neutropenia, pubmed-meshheading:7595717-Platelet Count, pubmed-meshheading:7595717-Recombinant Proteins, pubmed-meshheading:7595717-Regression Analysis, pubmed-meshheading:7595717-Sarcoma, pubmed-meshheading:7595717-Soft Tissue Neoplasms, pubmed-meshheading:7595717-Stomatitis
pubmed:year	1995
pubmed:articleTitle	Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
pubmed:affiliation	Sarcoma Group, French Federation of Cancer Centers: Fondation Bergonié, Bordeaux.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't